"Azathioprine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
| Descriptor ID |
D001379
|
| MeSH Number(s) |
D02.886.759.111 D03.633.100.759.534.090 D13.570.900.111
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azathioprine".
Below are MeSH descriptors whose meaning is more specific than "Azathioprine".
This graph shows the total number of publications written about "Azathioprine" by people in this website by year, and whether "Azathioprine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 2 | 2 | 4 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 6 | 6 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 3 | 4 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 3 | 3 |
| 2002 | 1 | 0 | 1 |
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 3 | 4 |
| 2011 | 1 | 0 | 1 |
| 2013 | 6 | 1 | 7 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2018 | 3 | 1 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 3 | 5 |
| 2022 | 2 | 0 | 2 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azathioprine" by people in Profiles.
-
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J. 2023 11; 62(5).
-
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Mult Scler Relat Disord. 2023 Jun; 74:104718.
-
Race, Genotype, and Azathioprine Discontinuation : A Cohort Study. Ann Intern Med. 2022 08; 175(8):1092-1099.
-
Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity. Clin Transl Sci. 2022 04; 15(4):859-865.
-
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30.
-
TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results. Clin Pharmacol Ther. 2022 01; 111(1):263-271.
-
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterol J. 2021 06; 9(5):552-560.
-
IgG 4 Autoimmune Hepatitis Presenting as Idiopathic Hypereosinophilia Syndrome. Hepatology. 2021 04; 73(4):1615-1617.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021 03; 160(4):1131-1139.